BACKGROUND: Uterine cancer is the fourth leading cancer among US women. Changes in uterine cancer staging were made from the American Joint Committee on Cancer (AJCC) 6th to 7th edition staging manuals, and 8 site-specific factors (SSFs) and 3 histologic schemas were introduced. Carcinomas account for 95% of cases and are the focus of this report. METHODS: Distributions of SSF values were examined for 11,601 cases of malignant cancer of the corpus uteri and uterus, NOS (not otherwise specified) diagnosed in Surveillance, Epidemiology, and End Results (SEER) Program registries during 2010. AJCC 6th and 7th edition staging distributions were compared for 11,176 cases using data in both staging systems. AJCC 6th edition staging distributions during 2004-2010 were examined. AJCC 7th edition SSFs required by SEER were International Federation of Gynecology and Obstetrics stage (SSF1), peritoneal cytology (SSF2), number of positive pelvic lymph nodes (SSF3), number of pelvic lymph nodes examined (SSF4), number of positive para-aortic lymph nodes (SSF5), and number of para-aortic lymph nodes examined (SSF6). RESULTS: For SSFs related to lymph nodes, a third of cases were classified as "not applicable," reflecting that lymph node dissection is not indicated for cases with stage1A and stage 4 diagnoses. AJCC 7th edition criteria assigned more cases to stage I (72.9%) than AJCC 6th edition criteria (68.7%). Annual counts significantly increased during 2004-2010, as did counts for AJCC 6th edition stages INOS, IA, IB, IC, IIIA, IIIB, IIIC, and IVB. The proportion of cases diagnosed with stage I cancer was stable, whereas stages II and IV decreased and stage III increased. CONCLUSIONS: Five SSFs were suitable for analysis: peritoneal cytology results (SSF2), numbers of positive pelvic lymph nodes (SSF3), pelvic lymph nodes examined (SSF4), positive para-aortic lymph nodes (SSF5), and para-aortic lymph nodes examined (SSF6). 
INTRODUCTION
Among cancers of the female genital system, corpus uteri and corpus, not otherwise specified (NOS) is the most commonly diagnosed cancer and the second most common cause of cancer death after ovarian cancer. Overall, uterine cancer is the fourth most frequently diagnosed cancer among women in the United States, with 49,560 newly diagnosed cases and 8190 deaths estimated to occur during 2013. 1 Incidence rates historically have been slightly higher among white women than black women and women of other races; however, the mortality rate among black women is almost twice that of other women. 2 Factors affecting racial variation include tumor aggressiveness and racial differences in the prevalence of hysterectomy. 3, 4 In recent years, the incidence rate of corpus uteri and corpus, NOS cancer has been increasing among women of all major racial and ethnic groups. Estrogen unopposed by progesterone is a main risk factor for endometrial cancer; and the increasing prevalence of obesity is thought to contribute to the recent increase in incidence. 5 Diabetes and nulliparity are both risk factors that are increasing among US women. 6, 7 The majority of cancer cases of the corpus uteri are diagnosed as International Federation of Gynecology and Obstetrics (FIGO) stage I. 8 Among more aggressive histologies, such as clear cell adenocarcinoma and serous cancers, cases often present at a more advanced stage and with worse prognosis. In these instances curative surgery may not be a treatment option.
Surgical staging of uterine cancers involves removal of the uterus, cervix, ovaries, and fallopian tubes and potentially dissection of the pelvic and para-aortic lymph nodes. 8 Biopsies are performed on areas of suspected metastases. Omentectomy is typically is reserved for more aggressive histologic subtypes. National Comprehensive Cancer Network guidelines for surgical management and use of lymphadenectomy for staging of endometrial cancer give consideration to preand intraoperative findings, extent of metastasis, and surgical risk associated with comorbidities. 9 Important prognostic factors of endometrial cancer are stage, grade, and lymph node positivity. [10] [11] [12] For surgical staging of gynecologic cancers, many countries follow standards set by FIGO. 13 The 7th edition of the American Joint Committee on Cancer (AJCC) Staging Manual, published in January 2010, includes the same staging categories as the FIGO staging guidelines of 2008, except that the AJCC 7th edition does not include IIICNOS or IVNOS.
14 Revisions in uterine cancer staging in the AJCC 7th edition, compared with the AJCC 6th edition, include but are not restricted to reassigning stage IIA cases to various subgroups of stage I and of some stage IIIA cases to stage I and II subgroups. In addition, approximately 15% of unknown stage cases under the AJCC 6th edition were reclassified to specific stages I, II, and II subcategories under the AJCC 7th edition. Like changes in FIGO staging guidelines, AJCC 7th edition revisions were made to improve the prediction of prognosis. 15, 16 Additional changes in the AJCC 7th edition include the collection of 8 sitespecific factors (SSFs), 6 of which were required by the Surveillance, Epidemiology, and End Results (SEER) Program: FIGO stage (SSF1), peritoneal cytology results (SSF2), number of positive pelvic lymph nodes (SSF3), number of pelvic lymph nodes examined (SSF4), number of positive paraaortic lymph nodes (SSF5), and number of para-aortic lymph nodes examined (SSF6). Collection of data for the other 2 SSFs, percentage of non-endometrioid cell type in mixed histology tumors (SSF7) and omentectomy (SSF8) were deemed optional. Another change was the separation of corpus uteri cancer cases into 3 separate histology-based staging schemas-carcinoma, sarcoma, and adenosarcoma. This report is restricted to the predominant schema, uterine carcinomas. We examined AJCC 6th edition staging trends during 2004-2010, the effect of the changes in staging criteria between the AJCC 6th and 7th editions, and the completeness of SSF data collected in 2010.
MATERIALS AND METHODS

Analytic Cohorts
The SEER November 2012 submission file was used for all analyses. Cases resided in 18 SEER registries covering 28% of the US population (also called the SEER-18): San Francisco (SF)-Oakland standard metropolitan statistical area, Connecticut, Detroit (metropolitan), Hawaii, Iowa, New Mexico, Seattle (Puget Sound), Utah, Atlanta (metropolitan), San Jose-Monterey (SJM), Los Angeles, Alaska Natives, rural Georgia, California excluding SF/ SJM/Los Angeles, Kentucky, Louisiana, New Jersey, greater Georgia.
International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3), 17 defines cancers of the corpus uteri by topography codes C54.0-54.3, 54.8, 54.9 and of uterus, NOS by ICD-O-3 topography code C55.9. The AJCC 7th edition classifies these cancers into 3 histological schema. Among diagnoses during 2010, corpus carcinoma (ICD-O-3 morphology codes 8000-8790, 8950, 8951, 8980-8981, 9700-9701) accounted for 11,821 cases (95.6%). An additional 478 cases (3.9%) were classified into the corpus sarcoma schema (ICD-O-3 morphology codes 8800-8932, 8934-8941, 8959-8974, 8982-9136, 9141-9582), and the remaining 60 cases (0.5%) belonged in the corpus adenosarcoma schema (ICD-O-3 morphology code 8933).
This report of AJCC 7th edition variables was restricted to malignant cancer cases belonging to the predominant schema, carcinomas of the corpus uteri. For the purpose of examining SSFs, 11,601 cases diagnosed in 2010 were included in the analytic cohort (Table 1) after 103 in situ cases were excluded because the updated FIGO staging system does not include this group, 113 cases were excluded because they were not microscopically confirmed, and 4 cases were excluded because they were diagnosed via autopsy or death certificate only.
The cohort for AJCC 6th and 7th edition staging comparisons was restricted to 11,176 cases after 425 additional cases with histologies not specified in the AJCC 6th The AJCC 7th edition includes in situ and preinvasive cases; however, the recent edition of the FIGO guidelines does not include in situ cases, and this report is restricted to malignant cancers only, which account for more than 99% of all reported cases. Research based on the AJCC 6th edition guidelines showed that stage IA (tumors confined to the endometrium) could not be distinguished reliably from stage IB (tumors that invade less than one-half of the myometrium), and in the 7th edition, they were combined as stage IA. Under the 7th edition, stage IB is reserved for tumors that invade one-half or more of the myometrium, 18 which were classified as stage IC under the 6th edition. Involvement in the endocervical glandular portion of the cervix was considered stage IIA under the AJCC 6th edition guidelines and is considered stage INOS, stage IA, or stage IB under the 7th edition. Involvement of the cervical stroma was classified as stage IIB in the AJCC 6th edition and remains stage II in the 7th edition. 19 The presence of cancer in ascites or peritoneal washings is downgraded from stage IIIA in the AJCC 6th edition to stages INOS, IA, IB, or II in the 7th edition because reports have shown that positive peritoneal cytology alone is not an independent prognostic factor if endometrial cancer is limited to the uterus. 20 In the AJCC 7th edition, cases with pelvic and para-aortic lymph node involvement were assigned to separate substages. Stage IIIC1 indicates positive pelvic nodes, and stage IIIC2 indicates positive paraaortic nodes with or without positive pelvic nodes, with the latter finding carrying a worse prognosis. 21, 22 The emphasis on examination of lymph nodes is reflected in College of American Pathologists (CAP) guidelines. 23 Severity also varies by schema. 24 Studies have shown that malignant cytology is associated with a negative prognosis and a higher rate of recurrent disease. 25 The 7th edition no longer requires peritoneal cytology for staging but continues to recommend its collection as an SSF. This shift is likely to be related to an increasing body of evidence supporting positive peritoneal cytology as an adverse risk factor only if there is other evidence of extrauterine disease. 26 Data regarding uterine sarcomas are not fully presented in this study. Sarcomas have a propensity for hematogenous spread and metastases. They were therefore placed in a separate schema from carcinomas in the AJCC 7th edition. 11, 27 Carcinosarcoma (formerly known as malignant mixed M€ ullerian tumors) continue to be staged as carcinomas. Adenosarcoma of the uterus is a rare mixed neoplasm that includes both a benign epithelial component and a malignant stromal element. These tumors typically are polypoid masses that arise from the uterine fundus. Most adenosarcomas are diagnosed as stage I and generally carry a good prognosis.
24,28
Summary of SSFs
Of 8 AJCC 7th edition SSFs introduced in 2010 for corpus uteri and corpus, NOS cancer (Table 2 ), 6 are required by the SEER Program for carcinoma, sarcoma, and adenosarcoma: FIGO stage (SSF1), peritoneal cytology results (SSF2), number of positive pelvic lymph nodes (SSF3), number of pelvic lymph nodes examined (SSF4), number of positive para-aortic lymph nodes (SSF5), and number of para-aortic lymph nodes examined (SSF6). Collection of SSF7 (percentage of non-endometrioid cell type in mixed histology tumors) and omentectomy (SSF8) were recommended by the AJCC but are not required by the SEER Program despite being included in the CAP cancer checklists. 23, 24 
Statistical Analysis
Database queries were performed with SEER*Stat v 8.0.2 (IMS, Calverton, MD). Annual percentage change in counts and 95% confidence intervals based on regression models were calculated using the SEER*Stat trend statistic option. Tables were populated using the FREQ procedure (SAS v 9.2, Cary, NC). Kappa statistics were calculated to assess agreement between AJCC 6th and 7th edition staging using the AGREE option of the FREQ procedure (SAS v 9.2, Cary, NC).
RESULTS
Cases
Trends in stage distributions for AJCC 6th edition corpus carcinoma, [2004] [2005] [2006] [2007] [2008] [2009] [2010] Among microscopically confirmed malignant corpus carcinoma cases meeting AJCC 6th and AJCC 7th edition staging criteria, the number of cases diagnosed with malignant corpus carcinoma increased each year from 2004 through 2010 (APC, 3.7; 95% CI, 3.3-4.5; Table 3 ). Statistically significant increases in annual counts were also observed in the annual number of cases diagnosed at AJCC 6th edition stages INOS, IA, IB, IC, IIIA, IIIB, IIIC and IVB. Despite the increase in case counts, the annual percentage of stage I cases remained at about 68% each year, with shifts from substage IB to IA and IC (Fig. 1) . After exclusions, the AJCC stage comparison data set included 11,176 cases (Table 4) . A total of 431 cases were moved from stages II and III according to AJCC 6th edition standards into stage I according to 7th edition criteria. In particular, endocervical glandular involvement was mapped to stage I in the 7th edition but not in the 6th (66.5% vs 63.0%), and fewer cases were classified as stages II or III in the 7th edition than in the 6th. Assessment of ascites and/or peritoneal washings also ceased to be used to define stage IIIA, resulting in fewer cases being classified as stage IIIA in the AJCC 7th edition compared with the 6th edition. Minimal changes occurred between the 6th and 7th editions for stage IV. Although staging agreement between the AJCC 6th and 7th editions is low (44%) overall, this primarily reflects the structural changes within stages I, II, and III.
SSFs
After exclusions, the SSF data set included 11,601 cases of carcinomas of the corpus uteri diagnosed in 2010 according to AJCC 7th edition criteria ( Table 5 ). The majority of these cases (68.3%) were diagnosed with endometrioid adenocarcinoma (ICD-O-3 morphology code 8380), with 46 other reported histologies (data not shown). Table 5 lists not applicable and applicable codes for analysis of the 6 SSFs. Applicable codes are further stratified into known and unknown values. All cases are "applicable" for FIGO Stage and Peritoneal Cytology because data would be expected on each case. However, the percentage of "not applicable" ranges from 37.3% to 64.1% for variables related to pelvic and para-aortic lymph node involvement because lymph nodes are most likely to be examined when biopsy or surgery is performed. Cases coded as "not applicable" were excluded from "known" versus "unknown" analyses for the SSFs. 
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Cancer December 1, 2014 derived from other stage data that are collected by the SEER Program. A comparison of SSF1, the collected FIGO stage, with AJCC 7th edition group stage found moderate agreement between the two variables (kappa, 0.55).
SSF2: Peritoneal cytology, corpus carcinoma
The presence of cancer cells in ascites or peritoneal washings was a criterion for stage IIIA classification in the AJCC 6th edition. Studies had shown that malignant cytology was associated with a negative prognosis and a higher rate of recurrent disease. 25, 26 Despite not being part of the 2008 FIGO staging system, data were known for 61.5% of corpus carcinoma cases. Table 7 indicates that 54.2% of the 2010 cases had negative peritoneal cytology, 7.2% had positive peritoneal cytology, and data were unavailable for almost 38.7% of cases.
SSF3: Pelvic nodes positive
There were 4323 cases (37.3%) for whom SSF3 was not applicable (Table 5) . Of the 7278 cases with pelvic lymph nodes assessed, 6966 (95.7%) had known values. Of these 7278 cases with pelvic lymph nodes assessed, 83.4% were classified as negative, 12.4% were classified as positive, and the result of the assessment was classified as unknown for 4.3% of the cases (Table 8) .
SSF4: Pelvic nodes examined SSF4 was not applicable for 4571 cases (39.4%); see Table  5 . This variable was applicable to 7030 cases, and 6372 (90.6%) of them had known values. Among cases for which pelvic nodes were examined, 40.3% were classified as having between 1 and 10 nodes examined, and 33.9% were classified as having had between 11 and 20 nodes examined ( Table 9 ). Analysis of the number of nodes examined by grade showed that cases with poorly or undifferentiated cancer were more likely to have dissected pelvic nodes examined than those with moderately or well-differentiated tumors (P < .001, data not shown).
SSF5: Para-aortic nodes positive SSF was not applicable to 6965 cases (60%). The variable was applicable to 4636 cases, and 4268 (92.1%) had known values. Of the 4636 cases with para-aortic nodes assessed (SSF 5), 82.7% were classified as having cancernegative nodes, 9.4% were classified as having positive nodes, and the information was unknown for 7.9% of the cases (Table 10) .
SSF6: Para-aortic nodes examined
Regarding SSF6, para-aortic nodes were not examined in 64.1% of cases (Table 5) . Among cases for which paraaortic nodes were examined, 68.7% were found to have had between 1 and 10 nodes examined, and 9.8% had between 11 and 20 nodes examined (Table 11) . Analysis of the number of nodes examined by grade showed that cases with poorly or undifferentiated cancer were more likely to have had dissected para-aortic nodes examined than those with moderately or well-differentiated tumors (P < .001, data not shown).
DISCUSSION
In the 7th edition of the AJCC, SSFs were incorporated for the first time, and extent of disease was expanded beyond anatomic extent alone. This reflects new insights regarding predictive and prognostically significant information. Of the 6 SSFs that currently are collected by the The ACOG guidelines state that retroperitoneal lymph node assessment is a critical component of surgical staging. 9 Patients without lymph node involvement may avoid adjuvant therapy and radiation. Both para-aortic and pelvic lymph node beds should be evaluated because retroperitoneal palpation is inaccurate and sentinel lymph node biopsy or pelvic lymph node sampling alone is unacceptable. Isolated para-aortic metastases are reported in up to 17% of patients. Lymph nodes may not be sampled when women with complex hyperplasia are diagnosed with uterine corpus cancer without surgical staging. Obesity also can impede access to the retroperitoneal space, and prolonged surgery may not be indicated for patients with severe comorbidities. Lymphedema, a chronic condition affecting a small percentage of women, also can influence decisions to perform a thorough lymph node dissection during uterine cancer surgery.
Analysis of the number of nodes examined by grade showed that cases with poorly or undifferentiated cancers were more likely to undergo pelvic and para-aortic node dissections than those with moderately or welldifferentiated cancers. This finding suggests that clinicians are particularly likely to obtain this information when patients have high-grade tumors.
Of the 3 uterine corpus cancer schemas, carcinomas account for more than 95% of cases, with an annual incidence rate approaching 25 per 100,000 women in 2010. 2 Trends for all uterine corpus and corpus, NOS cancers therefore mirror those for corpus carcinomas. Annual incidence rates of sarcoma and adenosarcoma were lower, in the range of 1 case per 100,000 women and 1 case per million women, respectively. In all 3 schemas, a handful of histologies account for a large proportion of cases. For carcinoma, the predominant histology was endometrioid carcinoma, followed by adenocarcinoma, NOS. For sarcoma, leiomyosarcoma, NOS was the main histology. Adenosarcoma was the sole histology in the third schema. We are unaware of major changes in ICD-O-3 codes for uterine corpus; however, subtle shifts in histologies are possible, and caution is warranted when assessing temporal trends by schema. Limitations include the collection of data in SEER registries only. These registries cover only 28% of the United States, and tend to have a higher proportion of foreign-born persons than the general US population.
In summary, some downstaging occurred in conversion from the AJCC 6th to the 7th edition. Most SSFs collected by SEER are suitable for analysis. The paucity of data on lymph nodes, with more responses among cases with high-grade cancer, may reflect when lymph node dissections are performed. Follow-up for survival can be used to assess SSF predictive value.
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